Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy

Serous tubal intraepithelial carcinoma (STIC) is considered the precursor of pelvic serous carcinomas and the earliest malignant alteration in BRCA mutation-positive women. Recently, risk-reducing salpingo-oophorectomy (RRSO) is being performed in BRCA mutation- positive women and STIC is often discovered incidentally in the fallopian tubes. A 62-year-old woman underwent bilateral salpingo-oophorectomy (BSO) for ovarian cysts. Ten months later, cytological screening for the endometrium revealed adenocarcinoma. No atypical tissue was detected by the endometrial curettage. Imaging tests and hysteroscopy found no abnormal findings. She underwent hysterectomy and was diagnosed with STIC originating from the intrauterine portion of the residual fallopian tube. Here, the authors report the first case of STIC being detected during an endometrial cytological examination after BSO. Although STIC associated with the BRCA mutation usually involves the distal fallopian tube, the present case suggests that the intrauterine portion of the fallopian tube should be removed or cauterized during RRSO.

Serous tubal intraepithelial carcinoma; Bilateral salpingo-oophorectomy; BRCA mutation.

[1] Delair D., Soslow R.A.: “Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum)”. Histopathology, 2012, 61, 329.

[2] Kurman R.J.: “Origin and molecular pathogenesis of ovarian highgrade serous carcinoma”. Ann. Oncol., 2013, 24, x16.

[3] Koç N., Ayas S., Uygur L.: “The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer”. Gynecol. Oncol., 2014, 134, 486.

[4] Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., et al.: “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship”. Am. J. Surg. Pathol., 2007, 31, 161.

[5] Lee Y., Medeiros F., Kindelberger D., Callahan M.J., Muto M.G., Crum C.P.: “Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer”. Adv. Anat. Pathol., 2006, 13, 1.

[6] Kuhn E., Kurman R.J., Vang R., Sehdev A.S., Han G., Soslow R., et al.: “TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions”. J. Pathol., 2012, 226, 421.

[7] Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., et al.: “The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome”. Am. J. Surg. Pathol., 2006, 30, 230.

[8] Visvanathan K., Vang R., Shaw P., Gross A., Soslow R., Parkash V., et al.: “Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study”. Am. J. Surg. Pathol., 2011, 35, 1766.

[9] Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E., et al.: “Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction”. J. Clin. Oncol., 2007, 25, 3985.

[10] Cass I., Walts A.E., Barbuto D., Lester J., Karlan B.: “A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers”. Gynecol. Oncol., 2014, 134, 492.

[11] Luzzatto R., Sisson G., Luzzatto L., Recktenvald M., Brucker N.: “Psammoma bodies and cells from in situ fallopian tube carcinoma in endometrial smears: a case report”. Acta. Cytol., 1996, 40, 295.

[12] Minato H., Shimizu M., Hirokawa M., Fujiwara K., Kohno I., Manabe T.: “Adenocarcinoma in situ of the fallopian tube. A case report”. Acta. Cytol., 1998, 42, 1455.

[13] Maeda D., Takazawa Y., Ota S, Takeuchi Y., Seta A., Nakagawa S., et al.: “Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear”. Int. J. Gynecol. Pathol., 2010, 29, 273.

[14] Chen S., Parmigiani G.: “Meta-analysis of BRCA1 and BRCA2 penetrance”. J. Clin. Oncol., 2007, 25, 1329.

[15] Finch A., Beiner M., Lubinski J., Lynch H.T., Moller P., Rosen B., et al.: “Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation”. JAMA., 2006, 296, 185.

[16] Mingels M.J., Roelofsen T., van der Laak J.A., de Hullu J.A., van Ham M.A., Massuger L.F., et al.: “Tubal epithelial lesions in salpingo- oophorectomy specimens of BRCA-mutation carriers and controls”. Gynecol. Oncol., 2012, 127, 88.

[17] Shaw P.A., Rouzbahman M., Pizer E.S., Pintilie M., Begley H.: “Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers”. Mod. Pathol., 2009, 22, 1133.